Novedades en la inmunoterapia de las enfermedades autoinmunes del tejido conectivo: parte I: lupus eritematoso cutáneo
Isabel Bielsa Marsol
[1]
[1]
Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Barcelona, España. Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, España
Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and
alternative treatment outcomes of antimalarial-refractory
cutaneous lupus erythematosus....
Chasset F, Bouaziz JD, Costedoat-Chalumeau N, et al. Efficacy
and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a...
Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for
treatment of cutaneous lupus erythematosus - guided by the
European Dermatology...
O’Kane D, McCourt C, Meggitt S, et al. British Association of
Dermatologists guidelines for the management of people with
cutaneous lupus...
Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus:
a multicenter, double-blind,...
Shipman WD, Vernice NA, Demetres M, et al. An update on
the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review....
Sonigo G, Jachiet M, Bessis D, et al. EMSED study group (Etudes
des Maladies Systémiques en Dermatologie). Hydroxychloroquine dose tapering...
Bourré-Tessier J, Peschken CA, Bernatsky S, et al. Association
of smoking with cutaneous manifestations in systemic lupus
erythematosus. Arthritis...
Piette EW, Foering KP, Chang AY, et al. Impact of smoking in
cutaneous lupus erythematosus. Arch Dermatol. 2012;148(3):
317–322. https://doi.org/10.1001/archdermatol.2011.342.
Erratum...
Chasset F, Francès C, Barete S, et al. Influence of smoking on
the efficacy of antimalarials in cutaneous lupus: a metaanalysis of the literature....
Francès C, Cosnes A, Duhaut P, et al. Low blood concentration
of hydroxychloroquine in patients with refractory cutaneous
lupus erythematosus:...
Chasset F, Francès C. Current concepts and future approaches
in the treatment of cutaneous lupus erythematosus: a
comprehensive review. Drugs....
Chasset F, Arnaud L, Jachiet M, et al. Changing antimalarial
agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus:...
Marmor MF, Kellner U, Lai TY, et al. American Academy of
Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine...
Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and
alternative treatment outcomes of antimalarial-refractory
cutaneous lupus erythematosus....
Keyes E, Jobanputra A, Feng R, et al. Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate...
Sievers QL, Petzold G, Bunker RD, et al. Defining the human
C2H2 cinc finger degrome targeted by thalidomide analogs
through CRBN. Science....
Chasset F, Tounsi T, Cesbron E, et al. Efficacy and tolerance
profile of thalidomide in cutaneous lupus erythematosus: a
systematic review...
Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al.
Thalidomide in the treatment of refractory cutaneous lupus
erythematosus: prognostic...
Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience
with low-dose thalidomide therapy in chronic discoid lupus
erythematosus. Int...
Briani C, Zara G, Rondinone R, et al. Positive and negative
effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity....
Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the
treatment of resistant cutaneous lupus: efficacy and safety of
different therapeutic...
Cesbron E, Bessis D, Jachiet M, et al. Risk of thromboembolic
events in patients treated with thalidomide for cutaneous
lupus erythematosus:...
Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, et al. Efficacy
and safety of lenalidomide for refractory cutaneous lupus
erythematosus....
Okon L, Rosenbach M, Krathen M, et al. Lenalidomide in
treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week...
Fennira F, Chasset F, Soubrier M, et al. Lenalidomide for
refractory chronic and subacute cutaneous lupus erythematosus: 16 patients. J Am...
Aitmehdi R, Arnaud L, Francès C, et al. Long-term efficacy and
safety outcomes of lenalidomide for cutaneous lupus erythematosus: a multicenter...
Kahlenberg JM. Rethinking the pathogenesis of cutaneous
lupus. J Invest Dermatol. 2021;141(1):32–35. https://doi.org/10.
1016/j.jid.2020.05.077.
Wenzel J. Cutaneous lupus erythematosus: new insights
into pathogenesis and therapeutic strategies. Nat Rev
Rheumatol. 2019;15(9):519–532....
Norris DA, Whang K, David-Bajar K, et al. The influence of
ultraviolet light on immunological cytotoxicity in the skin.
Photochem Photobiol....
Estadt SN, Maz MP, Musai J, et al. Mechanisms of photosensitivity in autoimmunity. J Invest Dermatol. 2022;142(3 Pt B):
849–856. https://doi.org/10.1016/j.jid.2021.05.007.
Zhou X, Yan J, Lu Q, et al. The pathogenesis of cutaneous
lupus erythematosus: The aberrant distribution and function
of different cell types...
Kuhn A, Herrmann M, Kleber S, et al. Accumulation of
apoptotic cells in the epidermis of patients with cutaneous
lupus erythematosus after...
Wenzel J, Wörenkämper E, Freutel S, et al. Enhanced type I
interferon signaling promotes Th1-biased inflammation in
cutaneous lupus erythematosus....
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and
safety of belimumab in patients with active systemic lupus
erythematosus: a randomized,...
Furie R, Petri M, Zamani O, et al. A phase III, randomized,
placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte...
Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized,
controlled trial of belimumab in lupus nephritis. N Engl J Med.
2020 Sep 17;383(12):1117–1128....
Vashisht P, Borghoff K, O’Dell JR, et al. Belimumab for the
treatment of recalcitrant cutaneous lupus. Lupus. 2017;26(8):
857–864. https://doi.org/10.1177/0961203316682097.
Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of
response and discontinuation of belimumab in patients with
systemic lupus...
Salle R, Chasset F, Kottler D, et al. Belimumab for refractory
manifestations of cutaneous lupus: a multicenter,
retrospective observational...
Kneeland R, Montes D, Endo J, et al. Improvement in
cutaneous lupus erythematosus after twenty weeks of belimumab use: a systematic review...
Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in
active systemic lupus erythematosus. N Engl J Med. 2020;382
(3):211–221. https://doi.org/10.1056/NEJMoa1912196.
Tummala R, Abreu G, Pineda L, et al. Safety profile of
anifrolumab in patients with active SLE: an integrated
analysis of phase II and III...
Chasset F, Jaume L, Mathian A, et al. Rapid efficacy of
anifrolumab in refractory cutaneous lupus erythematosus. J
Am Acad Dermatol. 2023;89(1):171–173....
Carter LM, Wigston Z, Laws P, et al. Rapid efficacy of
anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus...
Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2
antibody litifilimab for cutaneous lupus erythematosus. N
Engl J Med. 2022;387(4):321–331....
Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of iberdomide
in systemic lupus erythematosus. N Engl J Med. 2022;386(11):
1034–1045....
Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant
cutaneous lupus. JAAD Case Rep. 2021;20:61–64. https://doi.org/
10.1016/j.jdcr.2021.09.030.
Fetter T, Smith P, Guel T, et al. Selective janus kinase 1
inhibition is a promising therapeutic approach for lupus
erythematosus skin lesions....
Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic
lupus erythematosus: a double-blind, randomized, placebocontrolled, phase...
Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine
kinase 2 inhibitor, in systemic lupus erythematosus: a phase
II, randomized,...
Lim D, Kleitsch J, Werth VP. Emerging immunotherapeutic
strategies for cutaneous lupus erythematosus: an overview of
recent phase 2 and 3...
